Immunotherapy for Multiple Myeloma: A New Generation of Chimeric Antigen Receptors and Immune Checkpoint Blockade

Basic Information

Funding Cycle : 2022-2023
Name : Carlos Fernández de Larrea
Type of Award : Translational Research Award
Home Institution : Fundació Clínic per a la Recerca Biomèdica, Spain


Chimeric Antigen Receptor (CAR) T-cells targeting B-cell maturation antigen (BCMA) have proven outstanding efficacy and are a promising option for patients with relapsed/refractory multiple myeloma (MM), but no plateau is observed in progression-free survival (PFS) curves and relapses happen. One of the mechanisms of relapse is impaired T-cell persistence/potency due to T-cell exhaustion. Checkpoint inhibitory receptors (CIR) (E.g. PD-1, TIGIT) play a crucial role in T-cell exhaustion. Expression of TIGIT and its ligands has been reported in patients with MM and TIGIT blockade may reinvigorate T-cell function. Our institution has developed an academic, humanized BCMA CART, ARI0002h. The hypothesis of this project was that the efficacy of BCMA CAR T-cell therapy could be improved by blocking the immune checkpoint receptor TIGIT.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events